Simon Fricker
Overview
Explore the profile of Simon Fricker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Danthi S, et al.
ACS Med Chem Lett
. 2014 Jun;
3(3):216-21.
PMID: 24900457
A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing...
2.
Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, et al.
J Med Chem
. 2013 Oct;
56(20):8049-65.
PMID: 24090135
The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists...
3.
Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Langille J, et al.
Bioorg Med Chem Lett
. 2011 Oct;
21(23):6950-4.
PMID: 22033460
A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding,...
4.
Skerlj R, Bridger G, Zhou Y, Bourque E, Langille J, Di Fluri M, et al.
Bioorg Med Chem Lett
. 2011 Mar;
21(8):2450-5.
PMID: 21398122
A novel series of CCR5 antagonists were identified based on the redesign of Schering C. An SAR was established based on inhibition of CCR5 (RANTES) binding and these compounds exhibited...
5.
Calandra G, Bridger G, Fricker S
Curr Top Microbiol Immunol
. 2010 Apr;
341:173-91.
PMID: 20397073
Pharmacological manipulation of CXCR4 has proven clinically useful for mobilization of stem and progenitor cells and in several preclinical models of disease. It is a key component in the localization...
6.
Thakar M, Santos E, Fricker S, Bridger G, Storb R, Sandmaier B
Blood
. 2010 Jan;
115(4):916-7.
PMID: 20110438
No abstract available.
7.
Cytokines & inflammation--GTCbio's seventh annual conference. 29-30 January 2009, San Diego, CA, USA
Fricker S
IDrugs
. 2009 Apr;
12(4):214-6.
PMID: 19350461
No abstract available.
8.
AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates
Larochelle A, Krouse A, Metzger M, Orlic D, Donahue R, Fricker S, et al.
Blood
. 2006 Jan;
107(9):3772-8.
PMID: 16439684
AMD3100, a bicyclam antagonist of the chemokine receptor CXCR4, has been shown to induce rapid mobilization of CD34(+) hematopoietic cells in mice, dogs, and humans, offering an alternative to G-CSF...
9.
Chen J, Larochelle A, Fricker S, Bridger G, Dunbar C, Abkowitz J
Blood
. 2006 Jan;
107(9):3764-71.
PMID: 16439683
Current myeloablative conditioning regimens for hematopoietic stem cell (HSC) transplantation are associated with significant morbidity and mortality. Thus, alternative strategies to promote engraftment of infused HSCs with increased safety warrant...
10.
Burroughs L, Mielcarek M, Little M, Bridger G, MacFarland R, Fricker S, et al.
Blood
. 2005 Aug;
106(12):4002-8.
PMID: 16105977
Peripheral-blood mononuclear cells (PBMCs) mobilized with AMD3100, a CXCR4 antagonist, combined with granulocyte colony-stimulating factor (G-CSF) have reconstituted autologous hematopoiesis in cancer patients following myeloablative conditioning. The engraftment potential of...